Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Frozen-thawed Embryo Transfer in a Natural Cycle: hCG Triggering Versus LH Home Test
NCT03115320 · Tampere University Hospital · PHASE4 · terminated · last registry update 2024-08-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “High cancellation rate in LH test group in interim analysis” | – | Registry record, Tampere University Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against LHCGR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-18Results posted on the registry: Instituto Bernabeu, Corifollitropin Alfa + Follitropin Alfa (NCT05815719)
- 2025-04-27Results posted on the registry: Omayma Ismail Khalaf, hCG (NCT06684951)
- 2025-02-07Also stopped (terminated): Reproductive Medicine Associates of New Jersey, a drug against LHCGR (NCT06074055)
- 2024-12-13Results posted on the registry: Peter Kovacs MD, Follitropin Alfa + Follitropin delta (NCT05103228)
- 2024-12-09Phase 3 first posted: Shakeela Ishrat, Oxytocin + Human Chorionic Gonadotropin (NCT06725004)
- 2024-08-20Phase 3 first posted: Changchun GeneScience Pharmaceutical Co., Ltd., recombinant human follicle-stimulating hormone-CTP Fusion protein injection + recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo (NCT06561594)
- 2024-07-30Results posted on the registry: University of Illinois Chicago, a drug against LHCGR (NCT04616417)
- 2024-07-05Phase 3 first posted: Cairo University, Gonadotropin + Letrozole (NCT06486870)
- 2024-06-17Also stopped (terminated): Organon and Co, corifollitropin alfa + recombinant Follicle Stimulating Hormone (recFSH) (NCT00697255)
- 2024-05-22Also stopped (terminated): Fundacion Dexeus, Testosterone gel + Placebo gel (NCT02418572)
- 2024-05-17Phase 3 first posted: Ain Shams University, Alpha lipoic acid + Letrozole (NCT06418347)
- 2024-04-15Results posted on the registry: CRG UZ Brussel, Corifollitoropin alfa (CFA)-double pick up (NCT03846544)
- 2024-03-22Also stopped (terminated): Instituto Valenciano de Infertilidad, IVI VALENCIA, a drug against LHCGR (NCT04092829)
- 2024-02-28Also stopped (withdrawn): CRG UZ Brussel, Lutropin alfa + Follitropin alfa (NCT05405686)
- 2024-01-29Phase 3 first posted: Ellen Greenblatt, Luveris (NCT06227949)
- 2024-01-10Phase 3 first posted: Royan Institute, a drug against LHCGR (NCT06199960)
- 2023-12-14Results posted on the registry: Masonic Cancer Center, University of Minnesota, Pregnyl® (NCT02525029)
- 2023-11-07Results posted on the registry: Ferring Pharmaceuticals, MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL + MENOPUR powder and solvent for solution for injection, 75 IU (NCT04163458)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision